Company news

Aquestive Therapeutics, Inc. news in 2019

Aquestive Therapeutics, Inc.'s news releases, calls and decks from 2019, newest first.

View company

Aquestive Therapeutics Announces Pricing of Public Offering of Common Stock

December 11, 2019

Aquestive Therapeutics to Host Investor & Analyst Libervant™ (diazepam) Buccal Film Update Forum at American Epilepsy Society 2019 Annual Meeting

December 3, 2019

Aquestive Therapeutics Completes Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Libervant™ (diazepam) Buccal Film for Management of Seizure Clusters

December 1, 2019

Aquestive Therapeutics Announces Poster Presentations of Data on Libervant™ (diazepam) Buccal Film at American Epilepsy Society 2019 Annual Meeting

November 25, 2019

Aquestive Therapeutics Receives FDA Approval for Exservan™ (riluzole) Oral Film

November 24, 2019

Aquestive Therapeutics Licenses Riluzole Oral Film to Zambon for Development and Commercialization in the EU for Patients with ALS

November 12, 2019

Aquestive Therapeutics Reports Third Quarter 2019 Financial Results and Raises 2019 Guidance

November 4, 2019

Aquestive Therapeutics Reaffirms Full Year 2019 Revenue Guidance and Will Announce Third Quarter 2019 Financial Results and Recent Business Highlights on November 6, 2019

October 14, 2019

Aquestive Therapeutics Announces Successful Completion of Phase 1 Trial for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine)

September 29, 2019

Aquestive Therapeutics to Announce Second Quarter 2019 Financial Results and Recent Business Highlights on August 7, 2019

July 17, 2019

Aquestive Therapeutics Completes $70 Million Debt Refinancing

July 14, 2019

Aquestive Therapeutics Completes Enrollment in Libervant(TM) (diazepam buccal film) Crossover Study

June 3, 2019

Calls in 2019

Decks in 2019